StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — Sumeet Bagadia, Choice Broking

BUYSun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries share price target & all analyst calls

bySumeet Bagadia, Choice BrokingHorizon: NA (inferred Swing (≤2wk))31 Oct 2026via LiveMint Buy-or-Sell (topic)

Entry₹1,770Inferred
Target₹1,985
Total upside +12.15%
Stop loss₹1,690-4.52% risk
CMP₹1,8601d ago
Active+5.08%+6.72%upside left 9d left
Follow Sumeet Bagadia for new calls(30% target hit, 433 closed calls)Get alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 2 other Swing calls on SUNPHARMASee 204 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:25 pm IST
7 supporting3 neutral1 opposing
Supports the BUY call (7)

MACD above its signal line — bullish momentum

Technicals · macd·7 Nov · today

Past week's volume 1.8× the 30-day average

Technicals · volume·6 Nov · yesterday

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·6 Nov · yesterday

Sun Pharma shares extend 4-day rally after USFDA approval for ILUMYA in arthritis patients

NewsCnbc-Tv18·30 Oct · 1w ago

(opens in new tab)

Sun Pharma received U.S. FDA approval for ILUMYA (tildrakizumab-asmm) to treat adults with active Psoriatic Arthritis, expanding the drug's market reach.

BSE · Company Update·30 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (3)

Unaudited Financial Results for the quarter and half year ended 30 September 2026

NSE · Outcome of Board Meeting·30 Oct · 1w ago

(opens in new tab)

Sun Pharma to raise Rs 10,000 crore to part-finance Organon deal

NewsEt-Markets·21 Oct · 2w ago

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 3w ago

(opens in new tab)
Weighs against the BUY call (1)

RSI at 77 — overbought territory

Technicals · rsi·7 Nov · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Sun Pharmaceutical Industries

All analyst calls on Sun Pharmaceutical Industries

More from Sumeet Bagadia, Choice Broking

Every call and its outcome